Clinical Trial Update: UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating UB-VV410 in adults with active refractory systemic lupus erythematosus or lupus nephritis; recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• UB-VV410

Snippet

Sponsor: Nanjing IASO Biotechnology Co., Ltd. | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Status: RECRUITING